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In the absence  of an  experimental  bTLR8  structure,  recent  studies  have  called  attention  to the  fact  that
bTLR8  can also  be activated  by  hTLR7/hTLR8  agonist,  such  as  antiviral  imidazoquinoline  derivatives  of
resiquimod  (R848)  and  imiquimod  (R837)  as well  as  some  guanine  nucleotide  analogs  with  a  scaffold
structure  related  to  the  nucleic  acids  of ssRNA  virus.  In  particular,  the  known  small  agonists  (namely
CL075,  CL097  and  R848)  have  been  targeted  to  determine  distinguishable  deciding  factors  in  complex
with  dimeric  bTLR8-ECDs  in  comparison  to ligand-induced  activated  hTLR8-ECDs.  According  to basic
knowledge,  the  deciding  eligibility  criteria  can  be subsequently  applied  in  our bTLR8  model  to  character-
ize  the 3D-arrangement  of chemical  features  (pharmacophore)  and  to  investigate  the  distinct  restrictions
affecting  species-speciﬁcity  on  dual  TLR7/TLR8  small  agonists  suggested  in  previous  works.  Despite  the
lack of  extensive  structural  biology  studies  regarding  the  interaction  of  bTLR8-ECDs  with  the  agonists,
our  complex  models  of  bTLR8-ECDs  and  the  known  agonists  were  applied  to identify  the  deciding  factors
required  for  the  interactions  from  agonist-based  and  (bTLR8-agonist  complexes)  structure-based  phar-
macophores.  These  pharmacophore  constraints  impose  their  essential  chemical  features  to  active  bTLR8
receptors.  The  characterized  pharmacophores  all were  employed  in  the  virtual  screening  of  candidates
with  a further  acting  factor  of  calf  immune  enhancer.  Two  hits  were  suggested  as  satisfying  all  deci-
sion  factors  to  identify  a potent  bTLR8-speciﬁc  agent  with  novel  scaffolds  dissimilar  to  imidazoquinoline
analogues  lacking  overall  homogeneity.
© 2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
TLR8 is crucial for triggering innate immune response by recog-
izing conserved structural patterns of viral single-stranded RNA
ssRNA) and mediating antigen-speciﬁc adaptive immunity. TLR8
perates in endolysosomal compartments, where other TLR fam-
ly members participate in recognizing viral pathogen-associated
olecular patterns (PAMPs), including TLR3 (double-stranded RNA
r dsRNA produced during viral replications), TLR7 (ssRNA), and
LR9 (viral DNA). Most enveloped viruses (encompassed in ssRNA
irus of bovine viral diarrhea virus, BVDV) transport into the cyto-
ol through the endolysosomal compartments of the host. This
nderscores the subsequent immune response activation via the
LR7/TLR8 receptors by the ssRNA virus-invasion. Both the endo-
omal TLR7 and TLR8 receptors bring about the recognition of
∗ Corresponding author.
E-mail address: hanha@korea.kr (H.-H. Chai).
ttp://dx.doi.org/10.1016/j.ijbiomac.2016.08.022
141-8130/© 2016 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
identical PAMPs with some guanine nucleotide analogs in the
forms of uridine- and guanosine-rich viral ssRNA. They also share
functional and structural features [1]. Actually, the two TLR recep-
tors are germline-encoded in most vertebrates. Both genes from
bovine are very close to the locations of the X chromosome,
which is located 36.8 kb away from the coding exon of the other
gene [2,3]. However, these are mainly expressed in different cells
of the immune system; TLR7 is expressed in plasmacytoid den-
dritic cells (pDCs) and B cells, whereas TLR8 is predominantly
expressed in conventional/myeloid dendritic cells (cDCs), mono-
cytes, macrophages, and neutrophils of the mammalian host [4].
The endolysosomal environment is a primary determinant that
affects the interaction interfaces between TLR8 and its ligand to
form a more stable complex in conformity with the acidic invest-
ment at pH5.5, where they can target late endosome and lysosomes
[57,58], which have a pH5 [5]. Thus in acidic compartments at pH5.5
and below, their complementary electrostatic characteristics are a
signiﬁcant factor driving the ligand to adopt a bioactive confor-
mation oriented to the TLR8 binding pocket, depending upon the
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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esidue charges of the receptor and the chemical features of the
igand, such as its basicity. For example, regarding R848, which is
nown as a dual TLR7/8 agonist, the imidazo group of R848 has 6.9
Ka, so the agonist is positive-charge protonated at pH 5.0 and more
trongly interacts with several conserved acidic residues within
oth LRRs 17 and 18 on the inner concave surface of hTLR8-ECDs
5] in the acidic environment.
To date, thirteen crystal complex structures have been known
or TLR8’s small agonists bound to hTLR8-ECDs. Among them, one
tructure of dimeric hTLR8-ECDs, which has no ligand-binding,
as also determined in PDB. The ﬁve crystal hTLR8-ECDs dimer
tructures are cocrystalized with ﬁve different agonists (PDB code:
W3N, 3W3J, 3W3K, 4QC0, and 4QBZ). Their detailed information
s summarized in Table S1. Their various agonists, including the
bove ﬁve complex structures, are visualized in Fig. 1.
These complex structures provide insights into the ligand inter-
ctions of how TLR8 receptors recognize their molecular patterns
riginating from foreign viruses or external small agonists, but not
hat of host-self RNA in the endolysosome (from pH 4.4 to 5.2 in
rystallization experiments). It is not a question of whether they are
ble to discriminate between host-self and viral RNAs, rather than
he host-self RNA being degraded by an extracellular RNAase agent
efore sensing of the TLR8 receptor. The host-self RNA released
rom dying cells is rarely reaches into the endolysosome com-
artments. This biological process hinders an understanding of
ow TLR8 receptors contribute to the pathogenesis of autoimmune
iseases conjugated by the application of other imidazoquinoline
utgrowths (previously known as TLR8 agonists) for TLR8 antago-
ist [6,7].
We  can gain further information from 3D-structural superpo-
ition of the crystal structures that are aligned without major
onformational changes of the active hTLR8-ECD dimers induced
rom their ligand-binding. No remarkable main-chain RMSD was
bserved in 1.58 Å via rigid structural alignment using the jFAT-
AT program [8] which is freely provided on the PDB website
http://www.rcsb.org), when compared to conformers between
he hTLR8-ECD dimers after two small agonist-bindings (PDB
ode: 3W3N) from that of none ligand-binding (PDB code:
W3G). This is mainly due to the regular structural feature of
RRs within these ECDs; each of which consists of conserved
ydrophobic leucine rich-sequence motifs (continuous repetitions
f LxxLxxLxLxxN form) and exists with other conserved hydropho-
ic units (xФxxФxxxxFxxФx where x and Ф represent any amino
cids and other hydrophobic residues, such as leucine, respectively)
paced at distinct intervals (per 24–30 residues). The hydrophobic
otifs of LRRs form a series of asparagine ladders that have the
onﬁgurations of a -sheet and a 3–4 turned -helix connected
y loops. When the consensus LRRs are assembled to a TLR8-ECD,
heir hydrophobic residues are internally arranged in such a way
hat they act together to form a stable hydrophobic core from the
urrounding acidic aqueous investment. Consequently, the basic
CD LRRs that show a horseshoe-shaped structure have differently
rdered architectures on both sides; their inner surface is more
losely ﬁtted by well sorted parallel -sheets, whereas the outer
urface has irregularly organized -helixes and loops that allow
 curved releasing conﬁguration. For this reason, the inter-ladder
istances (35–45 Å) are substantially shorter than the larger outer
iameters (70–80 Å) for the overall hTLR8-ECD monomer struc-
ures [1] (in the current study, the curved horseshoe-shaped bTLR8
odel has a common structure frame with inner and outer dis-
ances of 44 Å and 82 Å respectively, too).
In the known hTLR8-ECD dimers in which each ECD binds aigand, the two ligand-binding sites are located on both lateral
nterfaces of an “M”-shaped ECD dimer immediately adjacent to
he acidic ambiences. Moreover, a large loop known as a Z-loop
between LRRs 14 and 15) and two conserved loops (in LRR 18cal Macromolecules 92 (2016) 1095–1112
and 20, respectively) protrude from the lateral surface and are
faced with the unit of ligand binding cavity (in Figs. S1 and 3).
Once again we recognized the importance of the ﬂexibility of these
loops within the acidic structural environment as a critical factor
for both ligand interaction and its recognition. On the other side,
the consensus motif of LRRs plays a key role in maintaining internal
protein-protein interactions within the middle of dimer architec-
ture, regardless of their ligand-binding. Speciﬁcally, the conserved
asparagine is involved in forming continuous H-binding networks
between neighboring LRR strands to construct the two horseshoe-
shaped monomers into a common “M”-template among TLR family
members. Furthermore, the stabilized “M”-template clasps both
other ends by capping the N-terminal and C-terminal regions with
conserved disulﬁde linkages; the LRR-NTs form a disulﬁde linked
-hairpin, while the LRR-CTs are held within two -helices by two
coupled disulﬁde bonds (NT and CT denote N-/C-terminal LRRs) [9].
If dimeric TLR8-ECDs directly interact with large ssRNA ligands,
the gaping “M”-shaped dimer will be more similar to the crystal
structure of homodimeric TLR3 ECDs/dsRNA complexes (PDB code:
3CIY). This can be fully predicted since TLR8 is directly connected
with the TLR3 in both their endosome localizations and recognition
of viral pathogen-derived RNA ligands. A comparison of the known
hTLR8-ECDs structures show that the “M”-shaped dimer makes
TLR8 receptors that are well suited for ligand-binding; therefore,
the dimerization of TLR8/TLR8 does appear to be a pre-requisite
for that. However, it can be conﬁrmed that the hTLR8-ECD often
shows only a monomer form on a small agonist-binding in the
solved structures (PDB code: 4R0A, 3WN4, and 3W3M) and the
dimerization of both TLR-ECDs could take place prior to ligand-
binding (bTLR8 undergoes homodimerization in the absence and
presence of R848 agonist-binding, such as hTLR8. Upon R848 bind-
ing, the dimerization of TLR8 continues without noticeable change
[5,10]). Solely, ligand-binding induces bioactive conformational
changes within the produced dimeric TLR8-ECDs. This leads to the
rearrangement of dimerization of both TLR8-TIR and a TIR of sig-
naling adaptor proteins, such as myeloid differentiation factor 88
(MyD88), in relation to each other according to a particular orienta-
tion forming a dimeric scaffold through hemophilic interactions of
their TIRs. This results in the stimulation of downstream signaling
cascades and the production of pro-inﬂammatory cytokines and
chemokines [11,12]. As a result, the TLR8 signaling for recruiting
host innate immunity elicits virus-induced type I IFN secretion by
dendritic cells (DCs) [13].
Notably, the structural alignments of dimeric hTLR8-
ECDs/agonist complexes in the PDB (PDB code: 3W3N, 3W3J,
3W3K, 4QC0, and 4QBZ) have also been shown to be governing
factors that determine the characteristics of their agonists-binding
patterns and the interaction constraints present in ligand-binding
sites. They all also play key roles in internal protein-protein inter-
actions in both C-terminal regions of each TLR8 monomer brought
into proximity for the structural stabilization of these complexes.
The structural superposition of the complexes is shown in Fig. S1.
The ligand-induced activated forms of hTLR8-ECDs are well aligned
as main-chain RMSD (root mean square deviations) values of 1.58 Å
(3W3N), 1.52 Å (3W3J), 1.71 Å (3W3K), 1.58 Å (4QBZ), and 1.48 Å
(4QC0), respectively, in comparison to that of the unliganded dimer
(3W3G), as seen in Table S1. Interestingly, these agonists that are
kept in the hTLR8-binding pocket are identically duplicated; their
chemical features are highly conserved in orientations that are
similar to the positioning of other ligand-induced hTLR8 structures
(in Fig. S1 and Table S1). The two  hTLR8-ECD monomers were far
away from the dimerization partners at the C-terminus regions
by ∼53 Å (in 3W3G), but upon small agonist-binding, they were
brought into closer proximity (30–34 Å) to the signaling complex
structure (within the ligand-induced dimerization structures rep-
resented in Fig. S1) [1]. Therefore, we have carefully analyzed the
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istinct differences in anticipation of monomer assembly among
he superimposed complexes (shown in Fig. S1) to determine
hether or not the complex structures fulﬁll the benchmarks
ased on the deciding factors.
In the absence of an experimental bTLR8 structure, recent stud-
es [10,14–16] have called attention to the fact that bTLR8 can also
e activated by hTLR7/hTLR8 agonists, such as antiviral imidazo-
uinoline derivatives of resiquimod (R848) and imiquimod (R837)
s well as some guanine nucleotide analogs with a scaffold struc-
ure related to the nucleic acids of ssRNA virus. In the regard, R848
ctivates TLR7/TLR8 from both human and bovine, whereas R837
electively activates TLR7 for only human; however, R837 is not a
peciﬁc agonist as a coactivator of both TLR7 and TLR8 receptors for
ovine [10]. In particular, the known small agonists (namely CL075,
L097, and R848) have been targeted to determine distinguishable
eciding factors in complexes with dimeric bTLR8-ECDs in com-
arison to ligand-induced activated hTLR8-ECDs [1]. As shown in
ig. S1, these small ligands overlap well the binding sites of hTLR8-
CDs, which may  match some common molecular determinants
ocated in bTLR8-ECDs. The matching determinants are consistent
ith the observed tendency of TLR8-mediated NF-B induction
apabilities to respond to agonist stimulations between human and
ovine TLR8s.
Liu et al. [15] suggested that the RQSYA motif (residues
38–442) in hTLR8-ECD had achieved the molecular epitope
overning these distinct agonist response efﬁciencies between
on-rodent and rodent TLR8s. TLR8 receptors from both usually
ave high structural similarity at the concave core, but may  have
ifferent lengths for some of the loops and different loop conforma-
ions depending on the type and location of sequence changes in the
nvironment proﬁle of non-conserved regions. Interestingly, this
QSYA motif is missing from the mouse and rat TLR8-ECDs, whereas agonists are employed in common feature pharmacophore generation.
it is maintained in its existing state with different correspond-
ing residues from non-rodent species. The ﬁve amino acid motif
is conserved with various residues of EQHDA (residues 431–435)
in bTLR8. Furthermore, the whole RQSYA motif deletion mutant
from hTLR8-ECD abrogates the ability to activate TLR8-mediated
NF-B induction response to its R848 agonist simulation, although
individual residues in the RQSYA motif indirectly interface with the
R848 agonist [15]. From the structural superposition and alignment
between hTLR8-ECD and modeled bTLR8-ECD, it was observed that
the RQSYA (corresponding to EQHDA for bTLR8) motif is located
at the junction between the LRR14 and Z-loop (40 residues long
between LRRs 14 and 15), which is at the deepest region of the
inner horseshoe surface. Thus, the hinge motif may additionally be
involved in TLR8-agonist interactions along with the Z-loop con-
former alignment. The Z-loop pushes out into the lateral surface of
the ligand-binding pocket with increasing size and importance of
the highest diverse residues in the protruding curvature portions
of the large loop. It seems likely that the ligand-induced conforma-
tional transitions of TLR8-ECD can be achieve with this increasing
importance if the Z-loop serves as a movable joint as it opens and
closes within an ‘M’-shaped dimer template. Therefore these hinge
motifs are allowed as the only part showing a high degree of species
traits in each ligand-recognition domain of TLR8, consistent with
this stretching TLR8’s bound pocket. The EQHDA motif from bTLR8-
ECD may  bring about intercepting interaction with its small agonist
so as to prevent them from continuing to a destination, while the
physicochemical properties of the motif outright affects the struc-
tural framework of the active site compared to that of hTLR8-ECD.
Thus common features and different deciding factors between the
activated signaling complexes for these TLR8-ECDs made require-
ments by particular circumstances analysis of the structure-based
agonist recognition.
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According to basic knowledge, the deciding eligibility criteria
an be subsequently applied in our bTLR8 model to characterize
he 3D-arrangement of chemical features (pharmacophores) and
o investigate the distinct restrictions affecting species-speciﬁcity
n dual TLR7/TLR8 small agonists suggested in previous works
10,14,15,17]. Despite the lack of extensive structural biology stud-
es regarding the interaction of bTLR8-ECDs with their agonists, our
omplex models of bTLR8-ECDs and their experimentally known
gonists [15] were applied to identify the deciding factors required
or the interactions from agonist-based and (bTLR8-agonist com-
lexes) structure-based pharmacophores. These pharmacophore
onstraints impose their essential chemical features to active bTLR8
eceptors. The identiﬁed pharmacophores all were employed in the
irtual screening of BVDV RdRp inhibitors to retrieve candidates
ith a more potent anti-BVDV drug as a further acting factor of a
alf immune enhancer.
. Materials and methods
All molecular modeling and optimization were performed in
iscovery studio, version 4.1 from BIOVIA (San Diego, USA) [52].
.1. Homology modeling of the bTLR8 receptor’s monomer
tructure
The crystal structures of the TLR8 receptor are well known
n humans including an unliganded preformed dimer (inactive
orm) and 13 small ligand-induced activated forms for the only of
he ligand-recognition domain of ectodomain (ECD). The bovine
LR8 protein sequence was matched to the template structure
f inactivated hTLR8 receptor (PDB code: A-chain of 3W3G) and
as mapped using the SwissProt protein database BLAST search
http://web.expasy.org/blast). The aligning sequence proﬁle was
hen compared to their conserved domain architectures in the pro-
eins of NCBI HomoloGene (www.ncbi.nlm.nih.gov/homologene/
. The homologue between human and bovine TLR8 receptors of
8% covered the entire sequence length (residues 18-1041, 1024
mino acids), showing a high sequence identity (74%), and a good E-
alue (<1 × 10−5). TLR8 receptors describe the distinctive domains
f an extracellular domain (residues 1-767) containing leucine-rich
epetition (LRRs) proﬁles [50] and a cytoplasmic Toll/IL-1 recep-
or (TIR) domain (residues 861-1008). Until now, the extracellular
omain in the TLR8 receptor has been investigated by X-ray crys-
allographic analysis; therefore, the ECD of the bTLR8 receptor was
redicted by homologues using only known hTLR8-ECD structures
from Arg32 to Leu819) where bTLR8-ECD would resemble the
emplate structure of hTLR8-ECD with 68.9% amino acid identity
ut be placed on the greater conformational similarities between
hem. The structure model of the bovine TLR8-ECD monomer (from
rg29 to Leu809) was then generated using the automated MOD-
LER program, while satisfying the diverse structural restraints
erived from the template’s structural features. The model struc-
ure of the bTLR8-ECD monomer is better optimized against the
omology restraints through the process of loop and side chain
eﬁnement by the CHARMm force-ﬁeld-based conjugate gradient
nd simulated annealing schemes (at physiological pH 5.5), when
he model structure has lower PDF total energy and DOPE score as
 measure of the model quality. The reﬁned models were validated
sing internal and external programs (PROCECK, ProSA, ModFOLD,
ERIFY-3D, and ERRAT).
.2. Knowledge-based protein-protein docking for bTLR8-ECDs
imerization
The dimerization of bTLR8-ECDs was executed with ZDOCK
o solve targeted initial-stage unbound bTLR8-ECD monomerscal Macromolecules 92 (2016) 1095–1112
docking, while the information about the binding-site-determined
hTLR8-ECDs dimer structure (the inactivated form of 3W3G) was
marked as ﬁltering binding site residues should be in the protein-
protein binding interface. Certain residues would appear in the
bTLR8-ECDs dimerization interface; for the receptor binding site
residues, Arg422, Ser485, Phe398, Val 371, Phe254, and Cys260
were selected, whereas, for the ligand binding site residues, the
Arg422, Phe487, Phe488, Tyr560, Phe561, Ala564 residues appear
earlier during the docking process. The rotational and transla-
tional space of the bTLR8-ECDs dimer was  investigated using the
fast Fourier transform (FTT) correlation algorithm with a 6◦ angle
sampling size. The docked poses (with the 54,000 poses clus-
tered according to ligand position) were ﬁltered for complexes
that included the set of residues at the dimerization interface of
bTLR8-ECDs that satisﬁed the following constraint. Then, 2000
docked poses that met  the ﬁltering criteria of the interface residues
were used to reorder the docked protein complexes by ZDOCK
score and the energy function with the ZRANK scoring function (a
linear combination of van der Waals attractive and repulsive ener-
gies, shor- and long- range repulsive and attractive energies, and
desolvation [51]). The poses were further reﬁned using CHARMm
minimization to optimize polar and electrostatic interaction. The
top 10 remaining poses was  employed to analyze the interac-
tions that occur there with H-bond, - interaction and salt-bridge
distance for the dimerization interface, compared to the anno-
tated hTLR8-ECDs dimer structure, yet again. In particular, the
loop region of LRR14 and the Z-loop missing conformer (residues
Asp436-Glu460) in the reference structure (hTLR8-ECDs dimers in
Table S1) were focused in the corresponding region of bTLR8-ECDs
(residues Asp429-Gln453). Small agonist recognition was mediated
by the dimerization interface and the Z-loop region where the key
residues are critical for agonist-binding and should be deﬁned on
the docked protein poses.
2.3. Docking TLR8 agonists into the putative binding site of
bTLR8-ECDs dimer complex
Whether the conformers of the preformed hTLR8-ECD dimer
(inactivated form) change or are maintained, particularly on the
agonist-binding on the induced ﬁt structure (activated form) is
very important to determine the docking method. Preferentially,
the structural superposition of the hTLR8-ECD/agonist complex (in
Table S1) were well aligned with the main-chain RMSD values of
less than 1.80 Å compared to that of the inactivated dimer (3W3G),
and then all agonists (in Fig. 1) were remained in the same binding-
position with highly conserved binding-geometries between them
(Fig. S1). Therefore, we  used a grid-based rigid docking method,
CDOCKER, for CHARMm-based docking scoring functions (interac-
tion energy plus ligand strain and the interaction energy alone)
calculated for each agonist-docked pose with random conformers
of docked agonists grouped into two binding site spheres via inde-
pendent iteration docking. The binding-patterns of the agonists
must be investigated for the hTLR8-ECDs complexes beforehand;
however, the CDOCKER program does not require any knowledge
of the two  binding sites of the bTLR8-ECD dimer or the binding-
decision constraints between them. Simply, to specify the agonist
placements located in the receptor cavities, the coordinates of the
binding site spheres should be deﬁned (such as the red areas in
the two  spheres in Fig. 3). In the CDOCKER process, the recep-
tor is rigidly considered, while the set of random initial agonist
placements are generated by high-temperature simulated anneal-
ing molecular dynamics with different random seeds. For each ﬁnal
pose, CDOCKER and CDOCKER interaction energies were calculated
(most negative thus favorable to binding) and the top ﬁve scor-
ing poses were retained for each agonist. After that, the consensus
scores (PLP1, PLP2, Jain, and PMF) of the series of docked poses of
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he TLR8 agonists were computed that those frequency of occur-
ence in the top rank percentile of each scoring function and their
igh scored binding-geometry in more than one scoring function
as listed. To gather knowledge regarding the signiﬁcant residues
nd non-bonded interactions involved in those deﬁnitive for high-
inding afﬁnity, we further analyzed the agonist docked poses with
n interaction histogram, which shows the key residues that form
he greatest number of interactions for those poses, so it is easy to
ompare the different interactions (Fig. 7).
.4. Creating bTLR8-ECD-agonist complexes structure based and
LR8 agonists common feature pharmacophores to screen
VDV-NS5B inhibitors
The best docked poses of bTLR8-ECD/agonist complexes were
tilized to explore the optimal intermolecular interactions with
n ensemble of steric and electrostatic features (pharmacophore
odel). The pharmacophore ensemble was interpreted according
o the essential features or chemical substructures as well as their
D location and, direction constraints that are responsible for the
harmacological interactions that TLR8 agonists undergo. For each
f the two binding sites of the bTLR8-ECD dimer (as the site sphere
ncluded in all residues within approximately 5 Å of their docked
oses shown in Fig. 3) an interaction map  was generated of H-
ond acceptors, H-bond donors, and hydrophobic features within
he agonist binding site sphere using the receptor-ligand phar-
acophore generation protocol. At this time, the steric location
f protein atoms near the binding site was reﬂected as excluded
olumes. We  considered information regarding the important six
esidues (Aap536, Asp538, Thr567, Phe398, Arg422, and Phe440)
nd their interactions with bounded agonists (Fig. 6) as criteria of a
easonable number of features corresponding with the six residues
f the binding site to select and edit the best model among the top
0 pharmacophore models.
On the other hand, the common feature pharmacophores were
enerated from the set of ﬁve TLR8 agonists shown in Fig. 1 on the
ssumption that the ﬁve agonists have similar activity for bTLR8
eceptors. The agonists conformational and pharmacophore space
ere previously searched under CHARMm force ﬁeld. Also, the
esired pharmacophore features and the agonist’s relative align-
ent with pharmacophores expressing these common features
ere explored via the docking result and receptor-agonist phar-
acophore model. As predicted, H-bond acceptors, H-bond donors,
s well as hydrophobic and hydrophobic aromatic features were
elected (Fig. S4). In addition, all of the chemical features in the ago-
ists were considered in the built pharmacophore space, and then
he agonists were mapped to all of the features in the ﬁnal phar-
acophores. The ten ranking common feature pharmacophores are
isted. Of them, we analyzed how well the agonists map  onto the
roposed pharmacophores by ﬁtness values and how they explain
he ﬁve agonists based on the overlay of key chemical features.
We performed a 3D pharmacophore search of 650 BVDV-NS5B
nhibitors by the above multiple pharmacophore models (the best
f structure-based and ligand-base pharmacophore models) to
dentify a potential bTLR8 agonist. Each pharmacophore model
ith ﬁve features allows up to four features to miss when the
VDV-NS5B inhibitors are mapped to the multiple pharmacophore
odels; the former bTLR8-ECD/agonist complex structure-based
eatures were the ensemble of two HBA and one HBD, and two
Y, while the latter agonist-based common features were the con-
guration of one HBA, one HY, two HBD, and one ring aromatic
epresented in Fig. S4. These 650 BVDV-NS5B inhibitors are struc-
urally different from the TLR8 agonists and have more diverse core
caffolds with more ﬂexible structures. The retrieved hits were
orted out by their ﬁtness values above 3.0 in the each pharma-
ophore model and anti-BVDV NS5B polymerase activity of pEC50cal Macromolecules 92 (2016) 1095–1112 1099
above 5.0, so they satisﬁed the ﬁltering condition of the excluded
volumes.
3. Results
3.1. The structure prediction and validation of bovine TLR8/TLR8
homodimeric complex
The 3D structure of bTLR8 is required to investigate novel
bTLR8 agonists and to discover leads of BVDV inhibitors from the
bTLR8 immune response. Homology modeling was used because
the TLR8-ECDs of mammalian hosts share a common structural
frame, and the substructures within the binding pocket include
similar ligands with similar scaffolds, but there are different
species-speciﬁcities for detecting them. Based on homology mod-
eling, the approach has been successfully expanded to rationalize
pharmacophore constraints based on bTLR8 receptor-agonist inter-
actions and to guide accurate binding modes and afﬁnities using
pharmacophore-restraint-based docking to identify potential hits.
The monomer structure of bTLR8-ECD was  generated by homol-
ogy modeling in which the unliganded form of hTLR8-ECD (PDB
code: A-chain of 3W3G) was selected as a template. Since bTLR8-
ECD shares 68.9% sequence identity and 81.6% sequence similarity
with the template, it should be closer to the conformation of the
TLR8 receptor in the physiological environment (the receptor func-
tions in the endolysosome compartment). The template structure
has a critical role to play in protein-protein docking to obtain
the assembly conformation and relative orientation of the pre-
formed bTLR8-ECDs dimer structure before its agonist binding.
The homology modeling was implemented using the MODELER
program available in Discovery studio (DS) 4.1 software [18]. The
reﬁned loop conformations and side chains after bTLR8-ECD model
generation were rearranged in regular order using statistical pair
potential and CHRMm force ﬁeld by a more extensive simulated
annealing procedure in the MODELER program. The modeled struc-
ture of bTLR8-ECD with the lowest probability density function
(PDF) total energy and discrete optimized protein energy (DOPE)
score was selected as an acceptable model for assessing the valid-
ity of the 3D-structure. The model is better optimized against the
homology restraints of the conformational similarities between
the template and model structures, when the bTLR8-ECD model
with the least violation of the hTLR8-ECD homology restraints is
preferred, and then the model has a lower PDF total energy and
DOPE score. As a result, the geometric features of the bTLR8-ECD
model (such as bond lengths, bond angles, dihedral angles and non-
bonded distances) were satisﬁed by conforming the energy proﬁles
with a reliable conformation in terms of geometric restraints on
their allowed values based on similarity with that of the template
(Table 1). The ﬁnal model of the bTLR8-ECD monomer contains 781
amino acid residues from Arg29 to Leu809, and then 26 units of
LRRs were assembled into the bTLR8-ECD model.
The reﬁned bTLR8-ECD monomer model was  then employed
as the receptor bTLR8-ECD and ligand bTLR8-ECD to predict the
bTLR8/TLR8-ECD dimer structure and to closely examine protein-
protein interactions for bTLR8-ECDs dimerization. TLR8 exists as
a dimer before the ligand-binding that we had been modeling
3D-structure assemblies of bTLR8-ECDs dimer through protein-
protein docking using ZDOCK program [19]. To explore the possible
rotational and translational space in ﬁtting together complemen-
tary parts for the TLR8 receptors assemblies, the 3W3G of the
hTLR8-ECDs dimer structure were subjected to guided positioning
into initial poses of the relative spatial positions and orienta-
tions between the bTLR8-ECDs monomers. If it was known that
some residues should be part of the protein-protein binding inter-
face, their starting positions were effectively captured in the
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Table 1
Model evaluation and the protein-protein interaction interface of bTLR8.
bTLR8 homodimer hTLR8 homodimer (3W3G)
PDF total energy 4,658.574 –
DPE  score −196,228.859 –
PROCHECK 98.1% 99.3%
ModFOLD Q/P 0.7217/0.000498 –
Verify 3D 96.93% 99.60%
ERRAT 76.197 81.694
Interaction surface area (Å2) The ligand polar interface: 846, 63 and non-polar
interface: 963.25 The receptor polar interface: 907.15 and
non-polar interface: 894.93
The ligand polar interface: 902.95 and non-polar interface:
756.19 The receptor polar interface: 866.73 and non-polar
interface: 780.54
Dimer interface: the residues of
protein-protein interaction
interface
A-chain: Phe254, Asn255, Pro257, Phe258, Pro259, Cys260,
Val371, Val396, Asn397, Phe398, Glu420, Asn421, Arg422,
Ser424, Ala435, Asn436, Ser439, Phe440, Gln441, Arg422,
Ser424, Ala435, Asn436, Ser439, Phe440, GLN441, Ser442,
His443, Ile444, Leu445, Lys446, Arg447, Gln453, Leu483,
Asn484, Ser485, Phe487, Ser507, Asn508, Gly509, Val513,
Arg534, Asp538, Asp539, Ile563, Ile564, Gly565, Val566,
Thr567, His568, Arg569, Leu570, Gly571, Phe590, Thr591,
Leu592, Thr593, Glu594, Leu614, Leu615, Asn617, Gln619,
Asdp620, Val621, Arg622, Tyr623, Asn669, Phe670,
Gln691, Phe693, Phe694, Arg715, Ser797, Glu802
A-chain: Phe183, Lys185, Cys260, Phe261, Asn262, Pro266,
Cys267, Val268, Pro269, Tyr348, Gly351, Ser352, Tyr353,
Val378, Gln380, Phe405, Lys407, Arg429, Ser431, Pro432,
Val434, Ser492, Phe494, Phe495, Tyr567, Phe568, Arg569,
Ile570, Ala571, Asp628
B-chain: Lys96, Gln98, Ser99, Gly100, Val104, Lys105,
Tyr176, Phe177, Asn255, pro257, Phe258, Pro259, Cys260,
Val396, Phe398, Glu420, Arg422, Gln441, Ser442, His443,
Ile444, Lys446, Arg447, Ala450, Ile452, Gln453, Leu483,
Phe487, Ser507, Gly509, Gln512, Val513, Asn532, Asn533,
Arg534, Asp536, Phe537, Asp538, His559, Tyr560, Phe561,
Arg562, Ile563, Ala564, Gly565, Val566, Thr567, His568,
Arg569, Leu570, Ile589, Phe590, Thr591, Leu592, Thr593,
Glu594, Gln596, Phe607, Asp613, Leu614, Leu615, Trp616,
Asn617, Ala618, Gln619, Asp620, Val621, Arg622, Tyr623,
Ile626, Arg644, Ser717, Gln739, Ser797, Gly799
B-chain: Phe183, Lys185, Lys266, Ser230, Leu250, Asp252,
Ser254, Cys260, Phe261, Asn262, Pro266, Cys267, Val268,
Pro269, Tyr291, Asn293, Tyr348, Gly351, Ser352, Tyr353,
Leu367, Ser368, Arg370, Val378, Gln380, Glu384, Gln388,
Met391, Gln392, Asn395, Phe405, Lys407, Asn416, Ser426,
Arg429, Ser431, Pro432, Val432, His464, Ser465, Asn466,
Phe467, Tyr468, Arg472, Ile475, Lys476, Gln478, Cys479,
Asp487, Ser489, Leu490, Ser492, Phe494, Phe495, Asn511,
Ser513, Ser522, Tyr534, Asp536, Asn546, Val558, Asp560,
Ser562, Tyr567, Phe568, Arg569, Ile570, Ala571, Val588,
Asn590, Glu612, Val614, Asp628, Arg643, Asn656, Leu660,
Phe678, Asn680, Thr682, Leu683
Note: PROCHECK: percentage of residues in most favored regions and additional allowed regions by analyzing residue by- residue and overall structural geometries, Mod-
FOLD  Q/P: the bTLR8 dimer model is consistent with a reliable conformation based on various combinations of structural features with that of the template 3W3G by satisfying
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onformational changes of interface space during the formation
f a homodimer complex from individual receptor and ligand
TLR8-ECD monomers. The space information of hTLR8-ECDs was
mmediately applied to ﬁx its starting orientation for the ligand
TLR8-ECD monomer relative to the receptor bTLR8-ECD monomer
t the initial-state unbound docking.
Before implementing the bTLR8-ECDs dimer model, we ﬁrst
onﬁrmed whether or not the native hTLR8-ECD dimer system
tated again as recapitulations of the docked hTLR8-ECD dimer
oses and of the binding interface of each hTLR8-ECD monomer’s
ose generated by a rigid-body docking of ZDOCK. The presented
op 10 docking poses (based on ZDOCK scoring) were likely to
e near the native docking conformation. The superimposed main
hains in the interaction interface between the best docked pose
nd the reference structure of the hTLR8-ECD dimer (3W3G) were
bserved within 2.0 Å RMSD of each other, and then their protein-
rotein binding interfaces were observed in 1232 Å and ∼1290 Å
1], respectively. The hydrophobic dimerization interface of the
nliganded hTLR8-ECD complex is composed of the residues of
RR11, LRR13-LRR15, and LRR18, which were superimposed well
n the docked complex of Tyr353, Phe405, Pro432, Phe494, Phe495,
nd Phe568. The contact information, which was generated by the
revious process, was analyzed to deﬁne the minimal orientations
ssential for covering the entire rotation space and to ﬁlter out con-
ormations that do not include the speciﬁed residues in the close
nterface.After conﬁrming the credibility of ZDOCK, we put the rigid-body
ocking of two bTLR8-ECD monomer models to practical use in the
onstruction of a bTLR8-ECDs dimerization model. After clustering
he binding poses (the locations of the poses indicate the centerent of protein models with the connection proﬁle between the 3D structure and
tructure by considering non-bonded atomic interactions which is greater than 50
of the binding interface on the ligand bTLR8-ECD protein structure
for each pose) according to the ligand bTLR8-ECD position, we  ﬁl-
tered possible complex poses, which are displayed as spheres at the
center of the binding interface between receptor and ligand bTLR8-
ECD monomers, by using a speciﬁed set of residues located at the
binding interface suggested by bTLR8-ECDs as a special constraint
corresponding to the prior-docked pose and the X-ray structures
from the hTLR8-ECD dimer. Using available information to force
residues to be inside the binding interface can reduce the num-
ber of assembly poses for the reﬁnement stage, and it can increase
the accuracy of the ﬁnal prediction. In addition, the scoring func-
tion (ZDOCK- ranking score) was  introduced to assess the shape
complementary, electrostatic, and desolvation effect against the
binding interface between two bTLR8-ECDs for the full set of docked
poses. The scoring function was calculated based on short- and
long-range repulsive and attractive interaction energies and des-
olvation under the CHARMm polar hydrogen potential [20] with a
pH of 5.5. Our constructed models of the bTLR8-ECD dimer showed
that, among the 54,000 sampled poses, 2000 poses would appear
in the protein-protein interface; therefore we  selected the 2000
poses. After reranking of the ﬁltered poses with speciﬁc residues
at the binding interface, the top reﬁned pose has the highest (best)
ZDOCK score (known as pairwise shape complementarity) and the
lowest energies of ZDOCK -ranking score (the desolvation, electro-
static and van der waals energy terms contribute to the score, which
is reduced to yield better results) of 24.76 and −153.67 kJ/mol,
respectively (Fig. 2).
Compared to the hTLR8-ECD template (3W3G), we  further
optimized the relative stability of the selected bTLR8-ECD dimer
model’s conformer with respect to statistical data collected from a
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Fig. 2. Predicted docked structure and the presented senior 50 poses with speciﬁc residues at the binding interface are shown as the top reﬁned docked ligand bTLR8 structure
(the  bTLR8 dimer ﬁnal schematic model colored with the ZDOCK-ranking score) and spheres belonging to the active poses. The locations of the spheres indicate the center
of  the binding interface on the ligand bTLR8 structure for each pose.
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oig. 3. Varying ligand binding patterns of two large insertions within LRR18 and 
eterminants. These insertions appear away from the ligand-binding regions of TLRatabase of other conformations with solved structures of a simi-
ar size using ﬁve external programs (PROCHECK [21], ProSA [22],
odFOLD [23], VERIFY-3D [24], and ERRAT [25]) to validate the
ptimized models. The quality of the bTLR8-ECD dimer model connected with TLR8s agonist-binding as the co-existence of multiple molecularwas evaluated both locally and by considering the residue-by-
residue geometry and overall stereochemistry (PROCHECK, ProSA,
ModFOLD) based on structural features. Ramachandran plots of
PROCHECK (in Fig. S2) as a ﬁrst check to verify predicted torsion
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ngles in the structurally reﬁned model showed the good stereo-
hemical quality of the predicted bTLR8-ECD dimer model; 781
esidues were built in the allowed region, with 81.5% of the residues
n the most favored regions, 16.6% in the additional allowed region,
.0% in the generally allowed region, and 0.8% in disallowed regions.
f the overall percentage is above 95%, then the protein model is
hought to be built correctly. For the bTLR8 dimer models, the
esulting ProSA-zcore (Fig. S2) was calculated to be around -9 of
he interaction energy per residue, which is similar to that of the
emplate (3W3G).
Moreover, we examined the ﬁtness of the characteristics of
hether the residue or the protein in the desired 3D environment
in the case of the bTLR8-ECD dimer, hydrophobic patches on the
urface of the model structure from the endolysosomal acidiﬁca-
ion at pH 5.5) by analyzing the verify- 3D score (VERIFY-3D), and
e evaluated the quality of the protein structure with the statistics
f non-bonded atomic interactions from highly reﬁned structures
ERRAT). For example, a low score is given to a polar residue in
he protein’s hydrophobic core. If the surface patch of bTLR8-ECD
onomer shows a low veriﬁcation score, it may  indicate that the
onomer is interacting with the other monomer and should be
uried internally. On the other hand, the correctness of the bTLR8-
CD dimer model was used to special criteria for judging the ﬁnal
odel is basically correct. The accuracy of the bTLR8-ECD dimer
odel can be assessed by the sum of 3D-proﬁles for its own  residues
nd based on VERIFY-3D and ERRAT. These score indicate whether
he model structure is reliable and may  be correct (not only to com-
ensate for length effect, but also to compare the core to those
btained using structures known to be correct by calculating the
D-1D self-compatibility scores for all structures in the PDB deter-
ined at a resolution less than or equal to 2 Å and with R-factors
ess than 20%). In our reﬁned model, 96.93% of the residues had
D-1D score ≥0.2 (at least 80% of amino acids having scored ≥0.2
n the 3D-1D proﬁle is a passing level) and 76.197 overall qual-
ty factor of non-bonded interactions (a score of greater than 50 is
cceptable). The evaluation results of the model, shown in Fig. S2
nd Table 1 clearly fall within the range of good quality and satisfy
he constraints imposed by these validation programs.
To understand how TLR8 receptors form an unliganded-dimer
omplex, it is essential to be able to identify the functional inter-
aces, which can serve as targets for structure-based agonist design
r guide site-directed mutagenesis for studying the bTLR8-ECD
imer structure-function relationship. The functional interface
esidues were sustained as those within the speciﬁed cutoff dis-
ance (9 Å) of the neighboring chain or residues, and analysis of
he interactions that occur there further conformed that all of
he residues were located in stable interaction environments. In
he current bTLR8-ECD interfaces, the ligand bTLR8-ECD (denoted
s the A-chain in Table 1) and receptor bTLR8-ECD (denoted as
he B-chain in Table 1) contact surface areas were 1809.9 and
802.1 Å2, respectively, while those of hTLR8 (3W3G) were 1659.1
nd 1647.3 Å2, respectively. Despite TLR8-ECD homodimerization,
he interface area of each monomer can be different because the
tructural orientation of a long loop (in particular a Z-loop) inserted
nto the interior and then the whole TLR8-ECD dimer structure has
n asymmetric contact surface. All of the protein-protein inter-
ction residues are listed in Table 1. Peculiarly, the interaction
roperties of lateral surfaces among the dimerization interfaces
ear the ligand-binding cavity may  be a deciding factor affecting
gonist-selectivity. Thus, the characterized residual interactions
nd contacts further increase the possibility that the bTLR8 dimer
odel can be applied to investigate its potential agonist interac-ions and the species-speciﬁcity of ligand recognition.
The ﬁnal monomer structure in the bTLR8-ECD dimer model is
omposed of a large, monomer horseshoe-shaped assembly from
6 LRR copies, a speciﬁc segment of the Z-loop (residues 426–465cal Macromolecules 92 (2016) 1095–1112
from bTLR8-ECD) located before LRR15, and two  terminal LRRs
(LRRNT and LRRCT). Remarkably, two long insertions (residues
557–568 within LRR18 and 611–623 within LRR20 of bTLR8-ECD)
are conserved in their lengths and directions on the structural char-
acteristics which are projected from the inside surface at LRR18
and LRR20, respectively (Fig. 3). The features of extended insertions
toward the inside surface lead to discontinuation of the organized
intervals between the arrays of 26 LRRs. Moreover, a major effect
on the two  insertions induced to small agonists can closely interact
with each other more than the monomer through the dimerization
of the ECD. Fig. 3 illustrates the ordered arrangements of the two
insertions on particular surfaces of the protein-agonist interaction.
Taken together, the topological alignment of the ligand-binding
pocket from the part of the Z-loop (residues 439–442 of bTLR8)
in which constituent parts are interrelated in the ligand-induced
TLR8-ECD active conformer, signiﬁcantly affects binding behavior
in terms of its afﬁnity and selectivity for agonist-interactions by the
continuous change of shape or passage size of the binding sites of
small agonists (Figs. 4 and 5).
3.2. Potential R848agonist-binding residues from bovine
TLR8/TLR8 dimer
If we  have knowledge about the signiﬁcant residues involved
in R848 binding to the bTLR8-ECD dimer or conserved active site
residues, we  can characterize either a distinct binding motif or
the essential chemical features of other agonists (CL075, CL097)
that are crucial for high-afﬁnity binding from the docked poses.
A comprehensive perception of the complex interactions between
the R848 agonist and bTLR8-ECDs would be descripted by trace
residues of the agonist-binding site. The evolutionary trace residues
are extracted from the agonist-binding site by the superimposed
TLR8-ECD dimer structures and multiple sequence alignments of
the special region (in particular to the Z-loop) in some vertebrates.
Also, additional interaction constraints result from sequence align-
ments within the part of two loop insertions (Fig. 3) and Z-loop
regions (Figs. 4 and 5) based on the similarity of the correspond-
ing TLR8-ECD dimer structures between human and bovine. When
a special region is classiﬁed by partitioning the protein sequence
alignments into subgroups where lie in the conserved functional
surface patches projected from the agonist-binding site within the
parcel of two  insertions and Z-loop. These trace residues can be
used to examine species-speciﬁc variation in the R848 agonist-
binding site from the interaction proﬁles. Figs. 3 and 4 display the
evolutionary trace residues. The trace residues are likely to make
a direct connection between conserved residues in the aligned
sequences (based on the set of selected residues from two  inser-
tions of LRRs 18 and 20 and the Z-loop) and their functional
speciﬁcity to achieve R848 agonist-binding. Where the confor-
mations of the hTLR8-ECD dimer do not change during small
agonists-binding (in Fig. S1), they can be induced to ﬁt a series
of agonist conformations into the key residues of a known bind-
ing pocket (listed in Table S1). Interestingly, the two  insertions (in
LRRs 18 and 20) and the Z-loop region clustered around the shape-
binding site based on the small agonists in the known locations
of hTLR8-ECD dimer-agonist complexes, produce a receptor cav-
ity of bTLR8 that is different from those of other species TLR8s (in
Figs. 3 and 4). This match suitability between the R848-agonist and
the binding site-shapes leads to corresponding variations govern-
ing the ligand-binding patterns in the similar hydrophobic cores
between them (Fig. 6).
To generate a map of interaction between bTLR8-ECDs and
R848-agonist, the trace residues for their inclusion were selected
among vertebrates from the putative binding site that corresponds
with important residues of the binding site from the template
structures of human TLR8-ECD/agonist complexes (listed in Table
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Fig. 4. From a multiple sequence alignment of the speciﬁc Z-loop regions among TLR8s from some vertebrates, residues within subgroups assumed to be essential for
maintaining TLR8 function as conserved residues, but are different between subgroups and are forced to mutate during evolution to make the distinction as class-speciﬁc
residues. The trace residues include the conserved residues and class-speciﬁc residues of TLR8s.
Fig. 5. Distinct ligand-binding pocket with its function of changing physical location or position of having its ligand interaction changed in part of the Z-loop from different
species TLR8s. The EQHDA motif (yellow) is not involved in the ligand-binding cavity, while it is located at the connection region of both helices in the LRR14 and Z-loop part
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Smmediately adjacent to the following LRR14. However, the SFQS motif (pink) is loc
hich  may  form an opening that improves access to that space. (For interpretation
f  this article.)
1). The putative binding site from bTLR8-ECDs shares a series
f highly conserved residues of Asp536, Gly565, and Thr567 in
ne monomer (A-chain) and Tyr346, Gly369, Val371, Phe398 in
he other one (B-chain) to those residues of hTLR8-ECDs. There,
midazo(thiazolo)quinoline derivatives, such as R848, CL097, and
L075 (in Fig. 1) would share similar binding patterns in the same
inding poses within the two pockets of the bTLR8-ECD dimer (Fig.
3) to those of the hTLR8-ECD dimer (Fig. S1).t the deepest section across the central region of a direct interaction with agonists,
 references to color in this ﬁgure legend, the reader is referred to the web version
The R848-agonist was docked from a speciﬁed starting struc-
ture with the R848-binding mode within the hTLR8-ECDs (PDB
code: 3W3N) into the putative binding site of bTLR8-ECDs. Multiple
docking poses were generated by simulation of annealing molecu-
lar dynamics with different orientations of the initial position. Then
the binding poses were subjected to CHARMm energy (interaction
energy plus ligand strain) and interaction energy alone employed in
CDOCKER [26]. With the best docking pose for the R848-agonist into
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TLR8-ECDs (with the most negative CDOCKER energy value, thus
avorable to binding) the main interactions with the bTLR8 receptor
ere maintained in a manner similar to that known for the hTLR8
eceptor (see Figs. 6 and S3). Two H-bonds are identiﬁed as satis-
ed with highly conserved residues, A:Asp536 and A:Thr567, while
he B:Phe398 and B:Arg422 residues play major roles in stabilizing
he substructure (aromatic ring) and maximizing the binding afﬁn-
ty of the R848-agonist through - stacking interactions. The two
nteraction sites of the bTLR8 dimer model are shown in Fig. S3.
The bTLR8-ECD/agonist complex model was available to char-
cterize a distinct binding motif or to identify more essential
esidues except the key interaction residues of A:Asp536, A:Thr567,
:Phe398, and B:Arg422 (Figs. 6 and S3). Additionally, the other
gonists (Table 2) with the determined binding structures to hTLR8
eceptor (solved complex structure with hTLR8 PDB code: 3W3J,
W3K, 3W3N, 3WN4, 4QBZ, 4QC0, 4R0A and 4R09, shown in Fig. 1,
nd the other known hTLR8 agonists, such as DS-877 [27], and uri-
ine mononucleotide [28]) were docked to the same binding site
f the R848-agonist into the bTLR8 receptor but not the ORN06S
ligonucleotide [28]. We  selected the best docked poses for each
gonist-binding by ﬁltering the scoring functions, such as CDOCKER
nergy, CDOCKER interaction energy, two piecewise linear poten-
ials (PLP functions of -PLP1 [29] and -PLP2 [30]), Jain scoring
unction (Jain) [31], and potential of mean force (PMF) [32], as
hown in Table 2. These scoring functions were used to identify the
gonist-binding modes that score highly in more than one scoring
unction and the frequency of occurrence in the top rank of each
coring function from multiple docking poses without requiring
ny information about their binding afﬁnities to bTLR8 receptor.
he docking scores were not perfectly consistent with previously
eported NF-B dependent luciferase activity [15], and they may in hTLR8 and bTLR8 receptors.
serve to explain the binding-trends of the agonists into bTLR8
receptor.
We  have further been tried to create knowledge about the
other signiﬁcant residues involved in agonist-binding to bTLR8-
ECDs and in their mutation effects, revealing conserved binding
site residues or those critical for high-afﬁnity binding. Focused on
the top ﬁve scoring poses of each agonist docked to the bTLR8
receptor, we generated their frequency histograms, which summa-
rize the key residues responsible for favorable interactions based
on the CDOCKER interaction energy for the best poses. Then it
was easy to compare the interaction count of ligand poses and
to list the most frequently encountered residues for each inter-
action type. As shown in Figs. 7 and S3, the B:Phe398, A:Asp536,
A:Thr567, B:Gln441, and B:Arg422 residues form the most common
favorable interactions with the docked poses for the eight ago-
nists. There are hydrophobic interactions and H-bond interactions.
Most H-bonds are formed with A:Thr567 and A:Asp536 as well as
B:Gln441, B:Arg422, and A:Asp538 residues that are also engaged
in the H-bond counterparts. The hydrophobic groups of ago-
nists are mainly positioned with a hydrophobic face consisting of
B:Phe398, B:Arg422, A:Val566, A:Val513, B:Phe440, and B:Ile444.
Additionally, several other residues participate in agonists-binding,
namely the B:Tyr341, B:Ser442, A:Gly565, A:Val566, B:Asn421,
B:Leu483, A:Tyr560, and B:Glu420 residues. The larger entrance of
the hydrophobic core in the interaction interface is, the more suit-
able it is for binding various agonists, may  be smaller extent of their
agonists-selectivity than that of the hTLR8 receptor (Figs. 6 and S3).
Fig. 7 shows all of the control agonists (R848, CL097, and CL075)
that are known to be active and are therefore used as controls in
bTLR8-ECDs as hTLR8-ECDs, make the criteria of being the highest
scoring poses (based on the CDOCKER interaction energy) form-
ing a hydrophobic interaction with the B:Phe398 residue and three
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Table  2
Docking scores of the best poses of the TLR8 agonists that are known 3D structures of the hTLR8-agonist complexes to the bTLR8 receptor.
Agonists CDOCKER energy
(kcal/mol)
CDOCKER interaction
energy (kcal/mol)
-PLP1 -PLP2 Jain -PMF
CL097 −88.66 −46.21 28.73 51.24 6.38 36.79
CL075  −71.03 −31.35 15.45 32.15 5.49 30.65
R848  −53.74 −21.27 21.4 28.07 1.88 19.32
DS-877 −275.23 −129.85 53.77 72.01 8.06 47.13
DS-802 −167.17 −86.44 48.8 49.2 7.76 33.47
XG-1-236 −221.78 −105.29 49.88 43.09 8.23 43.31
Uridine −93.49 −30.49 59.84 70.83 5.57 67.69
ORN06S −38.98 −8.31 11.33 14.96 1.62 18.11
Note: The scoring functions characterize various aspects of the receptor-ligand interactions against their binding afﬁnities and are generally referred to as knowledge-based
approaches, except the PLP function was developed as a docking function to correlate well with binding afﬁnities. The higher scores of -PLP1, -PLP2, Jain, and -PMF indicate
stronger  receptor-ligand binding afﬁnities but not CDOCKER energy and CDOCKER interaction energies (with the most negative energy values to favorable binding).
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n  our complexes model was surrounded mainly by the residues marked in pink.
-bond interactions with the B:Gln441, A:Thr567, and A:Asp536
esidues in agreement with the putative binding site described
bove. These properties help to conﬁrm the correct docking and
coring of bTLR8 control agonists and to distinguish them as being
f TLR8-mediated NF-B induction (biological testing was per-
ormed in NF-B-dependent luciferase activity [15]) affecting the
LR8 receptor’s activation from between human and bovine. As
nother possibility, the interaction residues (in Fig. 7) allow us to
pecify signiﬁcant residues with which agonists must form favor-
ble interactions, specifying whether any or all interactions are
equired.
Our docking study reveals that the binding sites in the bTLR8
eceptor were not located in equivalent positions of the complexes
ith the small R848-agonist and the short oligonucleotide ligand
f ORN06S (shown in Fig. 8) as it follow the remaining residues
take in the residues A:Gly511, A:Gln512, A:His568, B:Gly509, and
:Arg534), shown in Fig. 7, are only associated with the ORN06S
ocked poses. For the special purpose of H-bonding interactions,
he residues of B:Phe251, B:Asn255, and B:Tyr346 exist between
ridine, XG-1-236, and R848 agonists, respectively, as signiﬁcants with the eight agonists docked poses to the bTLR8 receptor. The interaction site
differences. The Val396 residue of the B-chain is related to R848,
DS-802 or XG-1-236 through hydrophobic interactions. In par-
ticular, for the ORN06S oligonucleotide, the best docked pose to
bTLR8 is placed on the inner concave surface arranged regularly
in -sheets rather than on the ﬂanked dimerization interfaces
(Fig. 8). The R848-agonist binding site is where the uridine lig-
and is also bound in a pose similar to that of other small agonists.
The relative proportions and transcribed architecture of the over-
all Z-loop conformers are constraints that are too important by
adding topological features to its contours of the ORN06S binding
site with regard to species-speciﬁc agonist recognition. In terms
of the ORN06S binding site benchmark, the docking results were
imaged into the meaningful difference between the two reference
crystal structures (PDB code: 3W3N and 4R09) since the binding
position and mode of ORN06S into the hTLR8-ECDs binding sites
are reﬂected to reﬁne the initial poses in those of the bTLR8 recep-
tor. Analysis of the docking results of small TLR8 agonists prompted
us to investigate the agonists-binding patterns focused on the role
of the Z-loop and the LRR18 insertion regions within the binding
site as well as key functional residues.
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.3. Identiﬁcation of key functional residues by the bovine
LR8/TLR8 dimer structure stability and R848 agonist-binding
ffects for generation of structure-based pharmacophore models
rom the complexes
The bTLR8 conservation patterns targeting to a selected motif
f the evolutionary trace residues within its binding sites should
eveal the deciding constraints of the ECD functional domain
or ligand recognition. If any trace residues have a linked
D-pharmacophore arrangement to common molecular features
mong multiple complex structures crystalized with small ligands,
his is a knowledge-based description of interaction constraints.
his is more reliable when pharmacophores are depicted as essen-
ial features (such as hydrophobic, H-bond acceptor, H-bond donor,
tc.) to trigger the TLR8 immune response. Moreover, their phar-
acophores corresponding to 3D locations of small ligands are
equired for the optimal intermolecular interactions with the TLR8
eceptor.
Preferentially, each trace residue is sorted according to residue
riority. The residue priority is determined by assessing the
LR8-ECD structural stability (in bTLR8-ECD dimer/R848-agonist
omplexes) and the binding effects of the TLR8-ECD/TLR8-ECD
onomers as well as the TLR8-ECD dimer/R848-agonist complexes
ia virtual site-directed alanine mutation against that of the wild
ype. It also infers the functional speciﬁcity of the trace residues as a
esult of the binding-site characterization. These pharmacophores
f major trace residues in turn lead to tune featuring conduc-
ors of the binding motif in the partial Z-loop region (shown in
igs. 4 and 5) for species-dependent activities of the TLR8 ago-
ists (R848, CL097, and CL075) [15]. As expected, the binding motif
within Z-loop) can be divided into two partition sequences that
how the functional speciﬁcity of whether it interacts with the
LR8 agonists or with the other TLR8 monomer upon the dimeriza-
ion. The SFQSHI binding motif (residues 439–444) from bovine is
irectly mapped to the binding pocket of TLR8 agonists in the com-
lex structure, while the EQHDA motif (residues 431–435) does not the R848 agonists and the ORN06S oligonucleotide ligands.
align at the site (Fig. 5). However, the EQHDA motif must be another
targeting region as it is of signiﬁcant value regarding interaction
interference to distinguish not-rodent from rodent TLR8s, and its
conformer exchange is crucial for the interaction of both bTLR8-ECD
monomers that cannot be easily blocked by small agonists.
To characterize a few key residues, we performed alanine
scanning mutagenesis on pre-selected residues, which are deci-
sive for the afﬁnity of the interaction of bTLR8-ECD/R848-agonist
complexes within approximately 5 Å of their docked poses.
Then we evaluated the effect of single-point mutations on
the binding-afﬁnity (mutation energy) of molecular partners in
bTLR8-ECD/bTLR8-ECD monomers and bTLR8-ECD/R848-agonist
complexes as the difference between the binding free energies in
their mutated structures and that of the wild type. Simultaneously,
the effect of mutations on bTLR8-ECD stability (under the bTLR8-
ECDs/R848-agonist complexes) is also considered as the free energy
difference between the folded and unfolded states of the TLR8
receptor. The corresponding mutation effects [33], the free energy
of which is calculated as sum of scaled van der Waals, electrostatic,
non-polar, and entropy terms, are presented in Fig. 9. A:Asp536,
A:Asp538, A:Thr567, B:Phe398, B:Arg422 and B:Phe440 within one
pocket of the two R848-agonist binding sites (showing in Fig. 6)
have a relatively strong impact on the mutation energies, which
showed different variations of mutation energy above 1.5 kcal/mol
before and after Ala mutants. All the six major residues of the bind-
ing site cooperate in not only binding to the R848-agonist but also
maintaining the bTLR8-ECD structural stability in the process of
inducing the active complex form by ligand-binding.
On the interactions of the cocrystalized structures with small
agonists in the hTLR8 receptor, the three-membered rings are in
the same position, and the imidazole group is in a similar position
to the thiazole or the oxazole functional groups in which the core
scaffolds overlay very closely on the imidazoquinoline substruc-
ture of R848 in the hTLR8-ECD/R848-agonist complexes (PDB code:
3W3N), except the nucleotide mimetic ligand of ORN06S (shown in
Figs. S1 and 8). Following the docked poses derived from the binding
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Fig. 9. Effects of single-point mutations on bTLR8 receptor stability (under the bTLR8 dimer-R848 complexes) and on the binding energy changes for bTLR8-bTLR8 monomers
and  bTLR8 dimer-R848 binding by mutating each key residue in the binding site of the bTLR8-R848 complexes to alanine. The mutation effect are deﬁned as follows: stabilizing
(mutation energy < −0.5 kcal/mol), neutral (−0.5 kcal/mol < mutation energy < 0.5 kcal/mol), and destabilizing (>0.5 kcal/mol).
Fig. 10. TLR8-quinoline agonist pharmacophore generation based on the interaction between the complex structures from bovine (a) the common feature pharmacophores
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n  the bTLR8-R848 complexes model. Pharmacophore features convert into a partic
-bond acceptor). (For interpretation of the references to color in this ﬁgure legend
ode of identical agonists, two H-bonds are also formed in which
he N atoms of the quinolone and of the imidazole groups to the
ide chain of Asp536 and the N atom of Thr567 within the bTLR8-
CD as does with the hTLR8; however the aromatic rings of these
gonists have weaker - stacking on the side chain of Phe398
f bTLR8-ECD than Phe405 of hTLR8-ECD. There, the 2-propyl
CL075) and the 2-ethoxymethyl (R848 and CL097) substituent
re inserted in the hydrophobic cavity formed by Tyr339, Tyr341,
ly369, Val371, Val396, Phe398, Phe440, Gly565, and Val573 of
TLR8-ECDs (Fig. 10). This cavity is less hydrophobic and shallower
han that of hTLR8; therefore, the entrance to the agonist-binding
ite is widened as shown in Fig. 6. These hydrophobic interactions
ay  be the fundamental cause of the reduced ability of bTLR8 to
ctivate NF-B-dependent luciferase, particularly in response to
he R848-agonist compared to the hydrophobic interaction effects
ith the counterpart residues of hTLR8 [15]. Surprisingly, mutants
:Asp538 and B:Thr567 to Ala have the biggest mutation effects
n R848-binding, as shown in Fig. 9, because of the ﬁtted geom-
try accordant with their location and the direction of formation-based pharmacophore features essential to interact with key binding site residues
olor-code (orange, aromatic ring; blue, hydrophobic; purple H-bond donor; green,
eader is referred to the web version of this article.)
of the H-bond to the ligand. From information about the known
interaction of hTLR8 residues [1], the leading pharmacophore fea-
tures of hydrophobic and H-bond interactions are well conserved
between hTLR8 and bTLR8 receptors, not but the action of arranging
their 3D-orientations through different paths. This suggests that
both TLR8-ECDs can be active by achieving the same of agonists
for hTLR8. Also, the species-speciﬁc trace residues between them
are within the superimposed agonists-binding sites. The binding
pocket was concentrated on the interactions of the bound crystal
structures of small agonists, when all occupied the same position
in both TLR8 receptors. It may  be interesting to generate an inter-
action map  for the six residues (Asp536, Asp538, Thr567, Phe398,
Arg422, and Phe440 without any replacing the well conserved
residues of hTLR8 by their pair sequence alignment) because their
interactions are important to TLR8-agonist binding. Even if avail to
use the interaction information for the original complexes struc-
tures as a template for positioning pharmacophore features, the
agonist-interaction interface includes the missing portion of the Z-
loop (residues 433–457) from the known hTLR8 complex structures
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Table S1) highlighted in the red box (the SFQRHI motif of hTLR8) in
ig. 4. However, our model region (corresponding to SFQSHI motif
f bTLR8) assigned in the class-speciﬁc trace residues of the Z-
oop was directly considered to create pharmacophores from the
igand-binding sites. Then, the interactions map  from the bTLR8-
CDs/agonists complexes is covered with the insights behind a
ombination analysis of favorable non-bonded interactions (Fig. 7)
nd single-point Ala mutation effect (on binding energy changes of
ig. 9) within the top scoring docking poses of the tested agonists
hown in Fig. 1.
At the exact 3D position of the agonists as location con-
traints where its circumstances control relative to the other
harmacophore features, structure-based pharmacophores were
enerated from observations corresponding to bTLR8 ECD/agonist
nteractions in the docked complex models. Coupled chemical fea-
ures were derived from the interaction type and relative locations
f the agonists rather than projected point features (H-bond accep-
or interaction point, hydrophobic interaction point, and H-bond
onor interaction point) of the targeted bTLR8-ECDs residues for
arking interaction sites. Then, shape constraint adds to surround-
ng their pharmacophores, as the excluded volume is deﬁned by
he cavity shape of the agonist-binding site of bTLR8-ECDs. As a
esult, the conﬁguration of the structure-based pharmacophores
s an arrangement of chemical features of two H-bond acceptors
HBA) and the features of one H-bond donor (HBD) vector as well
s two hydrophobic (HY) point features with location constraints
hat represent locations in space within a given radius. The radius
ndow with 1.6 Å for all feature points except projection points
.2 Å to account for all possible bioactive conformations of ago-
ists and the excluded volume of 1.2 Å, where the size of the
xcluded volume in the binding site expands to 5 Å. For the bTLR8-
CD/agonist binding site, the created pharmacophore model along
ith the interaction residues are shown in Fig. 10(b). One HBA is
riented toward Phe440, and the other HBA has projection orien-
ation toward Gly565. One HBD points toward the hydroxyl group
f Thr567, and two HY features are located at the centers of Arg422
nd Phe398, respectively. The remaining residues of the binding
ite placed by excluded volumes on these to use only ﬁltering cri-
erion for candidate against hits that are too large to occupy steric
egions from being identiﬁed in the subsequent database search
now shown in Fig. 10). It is observed that the key interaction
esidues and their interaction types in the interaction map  by a
eometrical pharmacophores are in agreement with the docked
esults and Ala-mutation effects in terms of the bTLR8-ECD/agonist
omplexes described above.
Among the known hTLR8 agonists, the bTLR8 receptor can be
ctivated by both the hTLR8 and hTLR7 agonists, which Liu et al.
15] and Zhu et al. [10]. suggested, with different NF-B luciferase
ctivities in response to the agonists in comparison to the hTLR8
eceptor. These agonists shown in Fig. 1 were therefore used to
eﬁne the common feature pharmacophores to activate the bTLR8
eceptor. This agonist-based pharmacophore model in which ﬁve
eatures comprise one HBA, one HY, two HBD, and one ring aromatic
matches aromatic rings with ﬁve or six member atoms shown in
range color at Fig. S4(a)), were farther overlapping on the one
BA, one HY, and on the reverse projection orientation of one HBD
gainst the already identiﬁed pharmacophore geometry of bTLR8-
gonist interactions (Fig. S4(c)). The overlapping pharmacophores
re also consistent with the interaction partners of bTLR8-ECDs
hat there is correspondence to Phe440 (HBA) and Phe398 (HY),
ut reverse oriented HBD replaces Thr567 to Ser442. Since the 3D-
patial arrangements of features are common to the quinoline class
gonists, those features can be superimposed on a particular con-
ormer on the basis of the similar types of substructure (as showing
n Fig. 10(a)) within the same binding site. This allows two pharma-
ophore sets to be aligned by RMS  displacement of 1.518 Å betweencal Macromolecules 92 (2016) 1095–1112
the matching features based on the location constraints (see Fig.
S4(c)).
4. Discussion
4.1. Insight into the TLR8-mediated immune response suppressed
by BVDV infection
The BVDV pastivirus is a major bovine pathogen that is well
characterized as a small enveloped virus with 12.5 kb of positive
sense ssRNA virus, as a surrogate model virus for the hepatitis C
virus in the same Flaviviridae family. The BVDV pathogen causes
a wide range of clinical symptoms as the infection progresses
to cause a fatal diarrheic state, known as mucosal disease. The
high vulnerability of claves to BVDV means that there is a higher
risk for newborn and young calves than older cattle in early life
immunity. Immediate attention is required for safe immuniza-
tion against this infection in early life. One promising strategy is
the use of TLR7/8 agonists as vaccine adjuvants to enhance the
innate immune protection of newborn and young calves against
the infection. The pathway of immunosuppression by BVDV strains
depends on the nature of the virus-infected cells and their cellular
responses to the biotype of BVDV (either non-cytopathogenic or
cytopathogenic) via the intracellular signaling molecules from the
bovine host [38–40,53]. In extreme case, virus infected cells are
related to their cell-type-speciﬁc expressed TLR7/8 receptors, and
then the cytokine patterns stimulated with each of these recep-
tors; if the peripheral blood monocytes are infected by the BVDV
intruder, dominantly stimulated the bTLR8 receptor as the primary
recognizer to the PAMPs than the bTLR7 receptor. Thereon, the bio-
logical difference between the biotypes of BVDV strain creates other
combinations of its damaging costimulatory molecules. For a spe-
cial object of the non-cytopathogenic BVDV strain, the induction
of interferon (IFN) type I is inhibited by the BVDV strain [54,56]
along with the regulatory transcription factors (IRF) 3 and 7, both
which are involved in the downstream signaling cascades of antivi-
ral innate immunity activated by TLR7/8 receptors. Interestingly,
the N-terminal protease (as an IFN antagonist) of the BVDV strain
interacts with the virus–induced phosphorylated IRF3 (that con-
trols interferon synthesis as TLR7/8 receptor signaling component)
of the bovine host that induces polyubiquitination and the subse-
quent proteasome-mediated destruction of IRF3 [41]. Overall, both
TLR7 and TLR8 receptors share the binding-patterns and character-
istic features of ssRNA viral PAMPs and small agonists focused on
their ECD domains, but there are functional differences between the
two receptors [42,43]. Thus, TLR8 receptor signaling follows from
NF-B activation [55], and subsequent proinﬂammatory cytokine
induction, such as TNF-, IL-12, mainly expressed in monocytes,
macrophages and myeloid dendritic cells, that TLR8 agonist did
act in the same way. On the other hand, the TLR7 agonist acti-
vates a TLR7-mediated immune effect via type I of INF and its
transcription regulators IRF 3 and 7 from plasmacytoid dendritic
cells, in which TLR7 receptors are predominantly expressed. We
further respected small TLR7/8 agonists to the species-speciﬁcities
and activations of TLR7/8-dependent immune responses via the
distinct signaling pathway within innate and adaptive immunity
to overcome the immunosuppression (such as inhibition of inter-
feron production in the host’s immune system) caused by the BVDV
pathogen. It was further observed that the bovine TLR8 receptor
can be activated by the human TLR7-speciﬁc and dual TLR7/8 ago-
nists. Both bTLR7/8 receptors respond to imidazoquinoline scaffold
agonists. Taken together, imidazoquinoline analogues have being
assessed to be valuable vaccine adjuvants that induce adult-like
levels of TNF- and IL-12 from neonatal antigen-presenting cells
in human newborns [7,44,45–48] and in newborn animals includ-
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ng calves, in which the functional and structural bTLR8 receptor
s similar to that of humans [49]. Moreover, the helper T lympho-
yte (type 1) responses follow from the TLR8 agonists effects on
ntigen-presenting cells due to prominent NF- B and JNK (c-jun-
-terminal kinase) arbitration.
.2. Understanding of the molecular principles of species-speciﬁc
igand recognition by TLR8 receptor
In the current study, we focused on the bTLR8-ECD, which
perates in recognizing the PAMPs from ssRNA virus (in particu-
ar BVDV) and has molecular discriminants that make it possible
o determine whether host immune responses are stimulated by
nown agonists, in order to identify a dual functional agent that act
s both bTLR8 agonist and a BVDV inhibitor. The ECD domain is the
ocation of multiple functional motifs, of which the SFQSHI motif
residues 439–444) in conjunction with the EQHDA motif (residues
31–435, corresponding to the RQSYA motif within hTLR8-ECD)
ithin the Z-loop plays a critical role in species-speciﬁc agonist
nteractions through its veriﬁed sequence and being arranged into
n entrance to the agonist-binding pocket (see Figs. 4 and 5). Sur-
risingly, the SFQSHI motif is characterized by the key interaction
esidues of Ser439, Phe440, and GLN441, which are concerned with
n HBA and HY center for the imidazo(thiazolo)quinoline deriva-
ives of TLR8 agonists based on their interaction pharmacophores
nd the common chemical features from the bTLR8-ECD/agonist
omplex model. On the other hand, all reference structures of
TLR8-ECDs are missing the SFQRHI motif (residues 446–451);
herefore, they are not involved in interaction with the R848 ago-
ist or either one of the CL075 and CL097 agonists (Fig. 4). The
hree residues (Ser439, Phe440, and GLN441) may  serve to activate
TLR8 with a geographical factor that decisively affects the upward
rend responding to the imidazo(thiazolo)quinoline agonists; the
igh activation order of CL075, CL097, and R848 agonists for bTLR8
s in contrast to that of CL075, R848, and CL097 for hTLR8 [15].
he Phe440 and Gln441 residues within the SFQRHI motif from
ovine are a geometric restriction vary in size on the hydropho-
ic pocket where there is ongoing reciprocal action between the
-propyl (CL075) and the 2-ethoxymethyl (R848 and CL097) sub-
tituent of the agonists and their hydrophobic residues. Thus, the
TLR8 activity easily inﬂuences the length and the chemical feature
f the 2-alkyl chain in the imidazo(thiazolo)quinoline derivatives.
L075 has the highest agonist activity for the bTLR8-ECDs, and
TLR8-ECDs did likewise. The dominant interaction restraint of
hese analogue agonists (R848, CL097, and CL075) is the electron
ensity of those 2-substituent that make a difference for their
nteraction strengths of the H-bonding and - stacking inter-
ction with the residues of ASP536, Thr567 and Arg422, Phe398,
espectively, via a combination of resonance and inductive sub-
tituent effect from the C2-electron donating group (EDG) adjacent
o the -system it more nucleophilic. As a result of this, the weaker
lky1 EDG on the hyper conjugated -system of CL075 makes
he stronger interaction strengths with bTLR8-ECDs. The compara-
ive docking study between bTLR8 and hTLR8 receptors for R848
gonist binding showed that lack of ﬁtness is closely related to
he basic characteristic of Arg422 (bTLR8) corresponding to the
yr353 residue (hTLR8) and the excursion of its quinolone ring
eing physically induced ﬁt docking to the - stacking interaction
ith Phe398 and then greatly decreased in bTLR8-mediated NF-kB
nduction as expected in Fig. 6. The compatibilities of small-agonists
re compared in Fig. 1. The bTLR8-ECD dimer determined the clear
nteraction constraints into pharmacophores of the quinolone ring
n both them whether to structure-based on bTLR8-ECD/agonist
omplex or ligand-based on the common features of these agonists.
his is well established in the unmistakable pharmacophore mod-
ls, where the hydrophobic aromatic ring and hydrophobic centercal Macromolecules 92 (2016) 1095–1112 1109
are located as common features of these analogues, but the revul-
sive feature is the only hydrophobic center lacking the hydrophobic
aromatic ring center on the quinolone ring due to their practical
interactions with the bTLR8 binding pocket (Figs. S4 and 11). Addi-
tionally, it diminishes the activities of TLR8 receptors from both
bovine and human, while the effectiveness of the R848-agonist is
lower than that of the CL075-agonist along with the terminal alkene
of the C2-substituent. The structural interaction of C2-ether oxy-
gen in R848 with hTLR8-ECDs is very well matched to HB2 (in the
PDB code 4R6A), in which only the 2-butyl chain is changed from
2-ethoxymethyl of R848 with its higher hTLR8-mediated helper T
cell 1-cytokine inducting activity (EC50 0.3 M of HB2 more effec-
tive than 1.0 M of R848) in whole blood assay [45]. Moreover, the
EQHDA motif with its hinge-like structure connecting the linked
helixes provides the determination of relative position and orienta-
tion of the Z-loop, which makes a difference in the protein-protein
interaction interface between bTLR8-ECDs. In accordance with the
moment acting on the hinge motif, the SFQRHI motif does whether
to have intensive effects on of the agonist interactions. The two
functional motifs are faced with changes in the local architec-
ture of the Z-loop together with the bTLR8-ECD dimer complex
into better tailored conformers induced by agonist-binding. Con-
sequently, there are recognizably different in relative effects of
bTLR8-ECD monomers on the behaviors of residues engaged in
protein-protein interactions (Table 1) and on protein-ligand inter-
actions (Figs. 7 and 9). Unlike some vertebrates, the SWRNRL motif
from mouse and rat TLR8-ECDs did not effectively act in the missing
movable joint motif in terms of ﬁve residues deletions; therefore,
the TLR8 receptor from these rodent species may  be required for
additional factors to achieve an immune response by agonists (with
neither mTLR8 nor rTLR8 respond to the CL075, CL097, and R848
agonists).
Also, from our docked poses for small agonists (in Fig. 1)
and ORN06S of oligonucleotide, the other species-speciﬁc motif
is located at a distinct binding site (Fig. 8) as well as hTLR8-
ECD/ORN06S complex structure (PDB code: 4R09). The ORN06S
oligonucleotide was predicted to have a completely different bind-
ing pattern and binding geometry corresponding to the interaction
counterpart residues against the former agonists; in the key -
 stacking interactions of His366, His462, Lys226, or Arg368 and
H-bonding of Asp336, Tyr284, and Lys307, or Asn393, His366,
GLN363, and Met364 in the two  binding pockets of bTLR8-ECDs,
respectively. The guanosine moiety of ORN06S showed weaker -
 stacking interactions and ineffective H-bonding in comparison
to the uridine mononucleotide docked to the same small agonist-
binding pocket, and the ORN06S binding afﬁnity to bTLR8-ECDs was
predicted to be much lower than that to hTLR8-ECDs (not shown).
4.3. Pharmacophore restriction-based virtual screening in small
BVDV inhibitors
The pharmacophore map  of the training TLR8 agonists can be
applied to an interaction descriptor that contain combinations of
substructures, 3D constraints, chemical features, and shapes of the
bTLR8 agonist-binding site, and then new tested ligands (as BVDV-
NS5B inhibitors) can be aligned to the pharmacophore geography.
Common features from ﬁve agonists were not clearly seen with
evident species-speciﬁc TLR8 responses for agonist recognition.
However, they may  be sufﬁcient to design a binary BVDV-inhibitor
based on the bovine host’s recognition of ssRNA virus of BVDV
and stimulate potent anti-viral immune responses in the capac-
ity of the virus NS5B RNA-dependent polymerase (RdRp) inhibitor.
To screen potential dual BVDV inhibitor candidates, we  prefer-
entially decided to search the 3D-pharmacophores based on the
ﬁtness of key chemical features in the set of small BVDV-NS5B
inhibitors with similarities to the ﬁve TLR8 agonists. If molecules
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among the BVDV-NS5B inhibitors) have very diverse fragments
r dissimilarity, they should be considered on some of the map-
ing features from the set of aligned ligands within all possible
ocations of the selected pharmacophore features. It is very impor-
ant to know how these inhibitors and physiochemical descriptors
rom our record-keeping BVDV-NS5B inhibitors [34] with various
caffolds (the data set of 650 molecules such as imidazopyridine,
enzimidazole derivatives had amassed from literatures) are satis-
ed by them screened with any interactions that are required to be
resent in every pharmacophore query from the bTLR8 receptor.
he set of 650 BVDV-NS5B inhibitors has a wide range of inhibitor
ctivity (from 0.04 M to 100 M of EC50, which is the amount
equired to achieve 50% protection of MDBK cells from BVDV-
nduced cytopathogenicity as determined by the MTT  method)
gainst the same binding target of BVDV NS5B polymerase, but their
ctivity values are unknown for bTLR8 receptors.
The main determinants for the speciﬁcity of agonists toward
LR8 receptors are the common features of bound agonists and the
nteraction map  of chemical features that hits are likely to satisfy
or the reasonable interaction with the agonists-binding site, and
hese have been used to enhance selectivity for bTLR8 receptors.
he BVDV-NS5B inhibitors can be mapped to any four features of
hose multiple pharmacophores that has either two  HY or one HY
nd one ring aromatic, one HBA, one HBD where substances are
uite different from satisﬁed hit molecules to the spaces of deﬁning
ach pharmacophore model. Based on these pharmacophoric fea-
ures from bTLR8/agonist interactions, potential hits were acquired
y either pharmacophore models with a ﬁt value above 3.0 and
EC50 (-log EC50) set to above 5.0 for anti BVDV-NS5B activity. The
loser the matching portion of the hit molecule is to the centroid
f the location constraints within the pharmacophore models, thef bTLR8 mapped on the multiplex chemical features and their shape constraints.
higher ﬁt value will be. The predeﬁned excluded volumes which
repose the region constraints where will sterically strike for hits by
a ﬁnal ﬁltering criteria after being aligned to the pharmacophores.
To identify new scaffolds of a potential candidate for a dual agent,
that is a bTLR8 agonist and a BVDV NS5B inhibitor, 9 hits were sat-
isﬁed for the multiple pharmacophore models based on both those
restrictions that ﬁtted to three classes of the core substructures
from BVDV NS5B inhibitors, resulting in 3 hit molecules remaining
that bear structural diversities (Fig. S5).
Among these remaining 3 hit molecules, the best hit (molecule
number 420 [35] was  6-chloro-9-(2-hydroxyethyl)amino-2-
methoxyacridine), which ﬁt all of the multiple pharmacophore
models with ﬁt scores of 3.63 and 3.50, respectively (Fig. 11).
The CL097 agonist retrieved by the common chemical features of
TLR8 agonists, showed a higher ﬁt score than the R848 agonist;
however, it did not show high ﬁtness for the structure-based
pharmacophore model induced by the bTLR8-ECD/R848-agonist
complex model. Moreover, the anti BVDV-NS5B effect of this hit
was evaluated with the pEC50 of 6.22 (with 0.6 of EC50 micromolar
inhibitor activity) in vitro. Next, we investigated the binding
mode of the hit molecule 420 compared to the known TLR8
agonists (shown in Fig. 1) with their interaction map  such that
the hit molecule should manifest H-bonding with Asp536, Thr567,
Ser439 and GLN441 and its hydrophobic moiety or aromatic ring
forms contacts with the hydrophobic pocket, including Phe398,
Phe440, and Arg422 along with docking to the bTLR8 receptor.
To highlight recurrent interactions (those having high probability
between the bTLR8-ECD/agonist complex models and the known
hTLR8-ECD/agonist complex structures), knowledge-based dock-
ing was applied on the hit by the geometrical pharmacophores
by pregenerating bTLR8-agonist interaction ﬁngerprints from the
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he 9-amino-6-chloro-2-methoxyacridine scaffold is mostly seen
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he N-substituted 2-hydroxyethyl group of the 9-aminoacridine
caffolds is known to strongly enhance anti-BVDV-NS5B activity
35]. As seen in Fig. S5, both molecules 131 [36] and 504 [37]
artially match all of the four chemical features encoded in the
ultiple pharmacophore models in comparison to molecule 420.
olecule 504 has one missing HBD feature for which it has a
maller ﬁt value than the former two molecules, and it may  be
ess active for the bTLR8 receptor according to the respective
tness (the EC50 of molecules 131 and 504 are 2.8 and 5.0 M for
nti-BVDV-NS5B inhibitor activities).
. Conclusions
The molecular modeling studies of the bTLR8 receptor sug-
est that the characteristics of binding geometries and binding
ecision factors are concentrated upon imidazoquinoline agonists
nto the bTLR8-ECDs dimer model by multiple pharmacophores.
he sets of pharmacophores are knowledge-based descriptors
cquired through theoretical understanding of the interactions
etween bTLR8/agonists and the common features of both ago-
ists. Collected interaction information has been applied to
escribe the species-speciﬁcity of these agonists correlated with
he functional motifs in the Z-loop in comparison for some verte-
rates. We  promote using the two geometries of pharmacophores
bTLR8-ECD/agonist complex structure-based and the common
eatures of the agonists-based) that participate in cooperativee
ecision-making to further virtually screen the known BVDV-NS5 B
nhibitors collected in our previous study. Two hits (molecules 420
nd 131 among 650 BVDV-NS5 B inhibitors) were suggested as sat-
sfying all decision factors to identify a potent bTLR8-speciﬁc and
nti-BVDV agent with novel scaffolds dissimilar to imidazoquino-
ine analogues lacking overall homogeneity.
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